AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)
75 Sidney Street, 4th Floor
355 articles with AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
AVEO Oncology announced results from the second prespecified analysis of overall survival in the TIVO-3 trial.
Shares of AVEO Oncology are climbing fast in premarket trading after the company released data that showed positive overall survival benefits of tivozanib in patients with highly refractory metastatic renal cell carcinoma who have received prior immunotherapy treatments.
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
AVEO Oncology reported financial results for the second quarter ended June 30, 2019 and provided a business update.
Kyowa Kirin Co., Ltd., and AVEO Oncology announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU.
AVEO Oncology announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT.
AVEO Oncology announced two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois.
AVEO Oncology reported financial results for the first quarter ended March 31, 2019 and provided a business update.
AVEO Oncology announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019.
AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA® in Spain
AVEO Oncology announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -AVEO
Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. and certain of its officers and directors.
AVEO Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 21,739,131 shares of common stock and short-term warrants to purchase up to 21,739,131 shares of common stock at a price to the public of $1.15 per share and accompanying warrant.
AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML
AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia (AML).
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company's kidney cancer drug, Tivozanib.
EQUITY ALERT: Rosen Law Firm Reminds AVEO Pharmaceuticals, Inc. Investors with Over $100K in Losses of Important Deadline in Securities Class Action Lawsuit - AVEO
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AVEO Pharmaceuticals, Inc. from August 4, 2016 through January 31, 2019, inclusive of the important April 26, 2019 lead plaintiff deadline in the securities class action lawsuit filed against the company.
AVEO Oncology reported financial results for the full year ended December 31, 2018 and provided a business update.
AVEO INVESTOR ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AVEO Pharmaceuticals, Inc. - AVEO
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AVEO Pharmaceuticals, Inc. from August 4, 2016 through January 31, 2019, inclusive.
RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AVEO Pharmaceuticals, Inc. between August 4, 2016 and January 31, 2019, inclusive.
3/1/2019Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.